Photocure ASA (PHO.OL) stock: Winston Score, insiders and Congress trades

Photocure ASA is a Norwegian biotech company that makes a medical drug used to detect bladder cancer. Its main product is Cysview (called Hexvix in Europe), a liquid solution that doctors put into the bladder before a procedure called cystoscopy. When exposed to blue light, cancer cells glow pink, making them much easier to spot than with standard white-light cameras alone. The company earns money by selling Cysview to hospitals and urology clinics, primarily in the United States and across Europe. With a gross margin above 90%, the business is highly efficient once the drug is sold — the main cost is sales and marketing, not manufacturing. Photocure's competitive position rests on its patented technology and the fact that Cysview is the only FDA-approved optical imaging agent for bladder cancer detection in the U.S. The key growth driver is expanding the number of hospitals that adopt blue-light cystoscopy, though the slow pace of clinical adoption remains the central risk to revenue growth.

Editorial rules set and reviewed by Felix Prehn, Economist and Editor. Figures are refreshed daily from Financial Modeling Prep and company filings; last refreshed 2026-10-06.